112,050 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Catalyst Capital Advisors LLC

Catalyst Capital Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 112,050 shares of the company’s stock, valued at approximately $2,019,000.

A number of other hedge funds have also bought and sold shares of TEVA. Allspring Global Investments Holdings LLC lifted its holdings in Teva Pharmaceutical Industries by 26.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 36,753 shares of the company’s stock worth $519,000 after acquiring an additional 7,763 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Teva Pharmaceutical Industries by 1.3% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,159,333 shares of the company’s stock worth $30,468,000 after acquiring an additional 27,713 shares during the period. Diversify Advisory Services LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $141,000. Nordea Investment Management AB raised its stake in shares of Teva Pharmaceutical Industries by 3.0% in the first quarter. Nordea Investment Management AB now owns 91,837 shares of the company’s stock valued at $1,299,000 after buying an additional 2,701 shares during the period. Finally, Daiwa Securities Group Inc. raised its stake in shares of Teva Pharmaceutical Industries by 3.7% in the first quarter. Daiwa Securities Group Inc. now owns 115,693 shares of the company’s stock valued at $1,632,000 after buying an additional 4,170 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TEVA shares. UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays boosted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $18.64 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a 52-week low of $8.55 and a 52-week high of $19.08. The business’s fifty day moving average is $18.03 and its 200 day moving average is $17.02.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.